ABBV250117P205000
- 26.27
- 0.000.00%
AbbVie Newsroom
BOCOM INTL: SIMCERE PHARMA (02096) successfully authorized AbbVie for its self-developed blood tumor/autoimmune tri-antibody on the TCE platform, receiving endorsement from the first MNC.
In the future, the company will actively explore the development potential of SIM0500 in the field of autoimmunity with AbbVie.
AbbVie Options Spot-On: On January 14th, 279.67K Contracts Were Traded, With 424.08K Open Interest
On January 14th ET, $AbbVie(ABBV.US)$ had active options trading, with a total trading volume of 279.67K options for the day, of which put options accounted for 2.31% of the total transactions, and
The Momentum Factor ETF Is Coming off a Great 2024 but Still Oversold
AbbVie Inc. (ABBV): An Undervalued Dividend Kings Stock to Invest in Now?
10 Health Care Stocks With Whale Alerts In Today's Session
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
AbbVie Goes Ex Dividend Tomorrow
AbCellera Expands Collaboration With AbbVie
AbbVie Inc. (ABBV) Is Attracting Investor Attention: Here Is What You Should Know
Express News | AbbVie collaborates with Xiansheng Zaiming to develop a candidate drug for multiple myeloma.
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
AbbVie To Go Ex-Dividend On January 15th, 2025 With 1.64 USD Dividend Per Share
January 13th (Eastern Time) - $AbbVie(ABBV.US)$ is trading ex-dividend on January 15th, 2025.Shareholders of record on January 15th, 2025 will receive 1.64 USD dividend per share on February 14th, 202
SIMCERE PHARMA's subsidiary has signed an overseas license option agreement with AbbVie for SIM0500.
SIMCERE PHARMA (02096) announced that on January 13, 2025, its subsidiary ShanDong SIMCERE Biopharmaceutical Co., Ltd. (ShanDong SIMCERE) entered into a licensing option agreement with a subsidiary of AbbVie Inc. (stock code: ABBV). Under the terms of the agreement, AbbVie will hold the licensing option rights for the investigational new candidate drug SIM0500. SIM0500 is currently undergoing Phase I clinical trials for patients with relapsed or refractory multiple myeloma (MM) in China and the United States. According to the terms of the agreement, the group will receive an upfront payment from AbbVie, as well as the most...
AbbVie (NYSE:ABBV) Is Paying Out A Larger Dividend Than Last Year
ConcertAI Presents at 43rd Annual J.P. Morgan Healthcare Conference: 2024 Results and 2025-2028 AI Solutions Roadmap
AbbVie, Simcere Zaiming Collaborate to Develop Bone Marrow Cancer Treatment
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
AbCellera Expands Discovery Partnership With AbbVie
Simcere Partners With AbbVie on Key Drug Candidate SIM0500
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma